Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

Daily exercise can work as well as second antidepressant drug

Exercise can be as effective as a second medication for as many as half of depressed patients whose condition have not been cured by a single antidepressant medication.

24 Aug 2011

Mood-related brain protein linked to sadness during cigarette withdrawal

Heavy smokers may experience sadness after quitting because early withdrawal leads to an increase in the mood-related brain protein monoamine oxidase A (MAO-A), a new study by the Centre for Addiction and Mental Health (CAMH) has shown. This finding, which was published in the Archives of General Psychiatry, may also explain why heavy smokers are at high risk for clinical depression.

3 Aug 2011

Positive results from levomilnacipran Phase III study for major depressive disorder

Forest Laboratories, Inc. and Pierre Fabre Medicament today announced preliminary top-line results from a Phase III study of levomilnacipran for the treatment of adults with major depressive disorder (MDD).

18 Jul 2011

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

Neuralstem, Inc. announced that it has received notice of allowance for U.S. Patent Applications 12/939,897 and 12/939,914 entitled: "Compositions to Effect Neuronal Growth."

15 Jul 2011

People with long term debilitating physical illness demonstrate mental resilience

People who have a long term debilitating physical illness demonstrate mental resilience according to Understanding Society, the world's largest longitudinal household study. The first findings reveal that people diagnosed with cancer, diabetes, respiratory or cardiovascular disease report similar mental health scores to those without physical illness.

11 Jul 2011

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

St. Jude Medical, Inc., a global medical device company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for expansion of its BROADEN (BROdmann Area 25 DEep brain Neurostimulation) study for depression. This expansion will allow a maximum of 20 sites across the U.S. to enroll up to 125 patients.

11 Jul 2011

People with long term debilitating physical illness demonstrate mental resilience

People who have a long term debilitating physical illness demonstrate mental resilience according to Understanding Society, the world's largest longitudinal household study.

11 Jul 2011

Early life adversity and prior depressive episodes make people become depressed more easily

We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.

30 Jun 2011

Simple non-invasive breath test could accurately detect vitamin B12 deficiency

Researchers have developed a new test to detect the levels of vitamin B12 using your breath, allowing for a cheaper, faster, and simpler diagnosis that could help to avoid the potentially fatal symptoms of B12 deficiency.

23 Jun 2011

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment in its Phase IIb clinical trial of Serdaxin to treat major depressive disorder (MDD).

22 Jun 2011

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.

22 Jun 2011

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

Alkermes, Inc. today announced the initiation of a phase 1/2 study of ALKS 5461 for treatment-resistant depression (TRD). ALKS 5461 is the combination of ALKS 33, a proprietary opioid modulator, and buprenorphine. TRD, which is also known as refractory depression, refers to depressive episodes that are not adequately controlled by standard antidepressant therapy.

15 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Venlafaxine Hydrochloride Extended-release Capsules, 37.5 mg (base), 75 mg (base) and 150 mg (base), the generic version of Wyeth's Effexor XR Capsules, which are used in the treatment of major depressive disorder and social anxiety disorder.

3 Jun 2011

New book on 'Overcoming Anxiety, Worry, and Fear'

Severe anxiety can leave its sufferers paralyzed with debilitating worry, uncontrollable fear and clinical depression. Although anxiety is the most common mental health problem in the U.S., many affected by anxiety don't know how to treat their problem or even how to seek help.

26 May 2011

Study examines effects of psychotherapy on cortisol stress hormone

In a study published in the current issue of Psychotherapy and Psychosomatics the effects of psychotherapy on cortisol, the most important stress hormone, are examined.

25 May 2011

Pitt researchers develop mouse model of major depressive disorder

Researchers at the University of Pittsburgh School of Medicine have developed a mouse model of major depressive disorder (MDD) that is based on a rare genetic mutation that appears to cause MDD in the majority of people who inherit it.

19 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Study: Dual medications do not hasten recovery from depression

Taking two medications for depression does not hasten recovery from the condition that affects 19 million Americans each year, researchers at UT Southwestern Medical Center have found in a national study.

3 May 2011

Major Depressive Disorder News and Research

Further Reading

Daily exercise can work as well as second antidepressant drug

Mood-related brain protein linked to sadness during cigarette withdrawal

Positive results from levomilnacipran Phase III study for major depressive disorder

Neuralstem receives U.S. patent allowance for three new neurogenic compounds

People with long term debilitating physical illness demonstrate mental resilience

FDA approves expansion of St. Jude Medical's BROADEN deep brain stimulation study for depression

People with long term debilitating physical illness demonstrate mental resilience

Early life adversity and prior depressive episodes make people become depressed more easily

Simple non-invasive breath test could accurately detect vitamin B12 deficiency

Enrollment complete in Rexahn's Serdaxin Phase IIb clinical trial for major depressive disorder

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Alkermes commences ALKS 5461 phase 1/2 study for treatment-resistant depression

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

FDA approves Mylan's ANDA for Venlafaxine HCl ER Capsules to treat depressive, anxiety disorder

New book on 'Overcoming Anxiety, Worry, and Fear'

Study examines effects of psychotherapy on cortisol stress hormone

Pitt researchers develop mouse model of major depressive disorder

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Naurex announces completion of $18 million Series A financing

Study: Dual medications do not hasten recovery from depression

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News